Introduction 47
In dogs, nodal marginal zone lymphoma (nMZL) is infrequent, representing 48 approximately 10% of all lymphoma histotypes diagnosed in this species (Valli et al., 2011) . 49
It was recently documented that nMZL is characterized by generalized lymphadenopathy and 50 is diagnosed at an advanced disease stage; thus, despite the indolent designation, the 51 prognosis is guarded (Cozzi et al., 2018) . 52
Adequate management of canine lymphoma requires accurate histological diagnosis 53 and comprehensive staging, which includes assessment of bone marrow (BM) involvement. 54
Therapeutic options rely mainly on the results of these procedures (Marconato et al., 2017) . 55
56
In dogs with diffuse large B-cell lymphoma (DLBCL), it has been shown that 3% BM 57 infiltration evaluated by flow cytometry (FC) identified cases with an unfavorable prognosis 58 (Marconato et al., 2013) . According to a recent study, peripheral blood (PB) and BM 59 infiltration occurred in 97.1% and 57.1% of canine nMZL cases, respectively (Cozzi et al., 60 2018). However, it is currently unknown whether different levels of PB and BM infiltration 61 may provide prognostic stratification in dogs with nMZL. 62
63
The aims of the present prospective study were to assess the influence of different 64 levels of PB and BM infiltration, detected by FC, on the duration of the first remission and 65 survival in dogs with newly-diagnosed multicentric nMZL, and to establish a cut-off value of 66 prognostic significance. 67 68
Material and methods 69

Inclusion criteria 70
A prospective analysis of dogs with multicentric nMZL was performed. To be enrolled 71 in the study, dogs were required to have complete clinicopathological data for analysis, and be 72
CA2.1D6, B-cells), and CD34 (clone 1H6, precursor cells). PB and BM samples were stained 99
with CD45, CD5 and CD21 antibodies. All antibodies but CD34 were provided by Bio-Rad 100 (formerly AbD Serotec; Oxford, UK); CD34 was provided by BD Pharmingen (San Diego, 101 CA, USA). Erythrocyte lysis was not necessary on LN samples, since haemodilution was 102 minimal, and double labeling using CD45 easily enabled the distinction between lymphoid 103 cells and debris or erythrocytes. Conversely, erythrocyte lysis was performed on PB and BM 104 samples by means of an erythrocyte lysis buffer containing 8% ammonium chloride, after were not included in the count of infiltrating neoplastic cells with our gating strategy. 120
121
Treatment and response evaluation 122
The treatment protocol was in keeping with approved standards. Dogs whose owners 123 wished to pursue immunotherapy received a 20-week dose-intense chemotherapy regimen, 124 consisting of L-Asparaginase, Vincristine, Cyclophosphamide, Doxorubicin, Lomustine, and 125 prednisone ( Response was evaluated at each chemotherapy session by measurement of peripheral 139
LNs. End-staging was carried out at the end of treatment, and every clinical, radiological, 140 ultrasonographic, or laboratory investigation that disclosed abnormalities at pre-treatment 141 staging was repeated. BM and PB were re-evaluated in all cases by FC. The end-staging 142 results were necessary to assess treatment response. 143
144
Statistical analysis 145
Time to progression (TTP) was calculated from the start of treatment to disease 146 progression (Vail et al., 2010) . Dogs lost to follow-up or dead for lymphoma-unrelated causes 147 before disease progression, as well as those in CR at the end of the study, were censored for 148
TTP analysis. 149
Lymphoma-specific survival (LSS) was measured as the interval between the start of 150 treatment and death for lymphoma (Vail et al., 2010) . Dogs alive at the end of the study, lost 151 to follow-up or dead due to causes other than lymphoma were censored for LSS analysis. 152
153
To detect possible associations between TTP and LSS, and PB and BM infiltration, 154 cases were subdivided into two groups based on the arbitrarily selected infiltration cut-offs of 155 1.0%, 3.0%, 5.0%, 10.0%, 20.0% and 30.0%. Thereafter, Kaplan-Meier curves were drawn 156 for each cut-off and compared using the log-rank test. Based on data distribution, the 30.0% 157
cut-off was not tested on BM samples. As two different BM cut-offs gave significant results 158 for LSS analysis, these were coupled to stratify the study population into three groups, which 159
were further tested by Kaplan-Meier curves and log-rank test. Mean BM infiltration at diagnosis was 6.86±9.39% (median 3.0%, range 0.2-51.6%). Table 2 . According to these results, cases were subdivided into two PB infiltration groups 222 (<30% and ≥30%) and into three BM infiltration groups (<1%, 1-20%, and ≥20%). 223
224
Concerning TTP, univariate Cox's analysis and log-rank test gave significant results 225 for substage (p=0.020 and p=0.017, respectively), treatment (p=0.037 and p=0.033, 226 respectively) and PB infiltration groups (p=0.006 and p=0.002, respectively) (Fig 1) . 227
Multivariate analysis showed significant results for treatment (p=0.012) and PB infiltration 228
groups (p=0.001). 229
Median TTP for significant variables is shown in Table 3 . 230
231
Concerning LSS, univariate Cox's analysis and log-rank test gave significant results 232 for substage (p=0.002 and p=0.001, respectively), LDH (p=0.050 and p=0.044, respectively), 233 PB infiltration groups (p=0.015 and p=0.008, respectively) and BM infiltration groups 234 (p=0.035 and p=0.022, respectively) (Fig 2) . Multivariate analysis gave significant results for 235 LDH (p<0.001), treatment (p=0.002) and BM infiltration groups (p<0.001). In particular, 236 dogs with BM infiltration <1% had a median LSS of 1403 days, whereas dogs with BM 237 infiltration of 1-20% and ≥20% had a median LSS of 337 and 188 days, respectively. 238
Median LSS for significant variables is shown in Table 4 . An elevated LDH activity at initial diagnosis was predictive for shorter survival. This 274 is in agreement with a previous study, whereby it was shown that elevated LDH activity was 275 more frequent in dogs with DLBCL and higher PB and BM infiltration, possibly indicating a 276 marked disease activity. Also, in the same study, high LDH activity predicted a more Second, the FC strategy used to quantify PB and BM infiltration in the present study 308 has never been validated for canine nMZL, but was derived by the one used to stage canine 309 large B-cell lymphomas (Riondato et al., 2016) . In particular, we lowered the FSC threshold 310 in order to include medium-sized cells in the count. This likely affects the analytical and 311 diagnostic performances reported. In particular, the limit of detection (LOD) of medium-large 312 CD21+ cells in non-neoplastic samples is likely higher than the one reported for large B-cells, 313
and even higher than 1%. Nevertheless, we report relevant prognostic implications only for 314 
Conclusions 321
The detection of PB and BM involvement in most dogs with nMZL confirms the need 322 for PB and BM flow cytometric evaluation as an integral part of staging work-up also in these 323 patients. We found that PB infiltration ≥30% and BM infiltration ≥20% in dogs with nMZL 324 are independent negative prognostic factors. More specifically, in dogs with PB infiltration 325 <30%, BM evaluation stratifies dogs into 3 prognostic groups: those with a poor (infiltration 326 
